Drugs / Andrographis paniculata Extract (ApE)
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT02280876 Comparator | Jan 2012 → Feb 2015 | relapsing-remitting multiple sclerosis | Universidad Austral de Chile | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Andrographis paniculata Extract ( ApE ) | “Andrographis paniculata Extract (ApE), Oral tablets 650 mg, with 170 mg. of andrographolides active principles, three times per day, during a total of 365 continuous days.” NCT02280876 ↗1“Andrographis paniculata Extract ( ApE )” NCT02280876 ↗ |
| Known as | ApE | “Andrographis paniculata Extract (ApE), Oral tablets 650 mg, with 170 mg. of andrographolides active principles, three times per day, during a total of 365 continuous days.” NCT02280876 ↗ |
| Route | Oral | “Oral tablets 650 mg” NCT02280876 ↗ |